301. Macular dystrophy Clinical trials / Disease details
Clinical trials : 45 / Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01625559 (ClinicalTrials.gov) | September 2012 | 18/6/2012 | Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) | A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD) | Stargardt's Macular Dystrophy | Biological: MA09-hRPE | CHABiotech CO., Ltd | NULL | Active, not recruiting | 20 Years | N/A | Both | 3 | Phase 1 | Korea, Republic of |
| 2 | NCT02445612 (ClinicalTrials.gov) | July 11, 2012 | 13/5/2015 | Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients | Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Stargardt's Macular Dystrophy | Biological: MA09-hRPE | Astellas Institute for Regenerative Medicine | NULL | Completed | 18 Years | N/A | All | 13 | Phase 1/2 | United States |
| 3 | NCT01469832 (ClinicalTrials.gov) | December 13, 2011 | 8/11/2011 | Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Stargardt's Macular Dystrophy | Biological: MA09-hRPE | Astellas Institute for Regenerative Medicine | NULL | Completed | 18 Years | N/A | All | 12 | Phase 1/Phase 2 | United Kingdom |
| 4 | NCT01345006 (ClinicalTrials.gov) | June 16, 2011 | 28/4/2011 | Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy | A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) | Stargardt's Macular Dystrophy | Biological: MA09-hRPE | Astellas Institute for Regenerative Medicine | NULL | Completed | 18 Years | N/A | All | 13 | Phase 1/Phase 2 | United States |